In vitro activity of ceftolozane-tazobactam and other antimicrobial agents against burkholderia cepacia complex and burkholderia gladioli

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 9, 2017, Pages

  Mazer, Dale M ^a   Young, Carol ^a   Kalikin, Linda M ^a   Spilker, Theodore ^a   LiPuma, John J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Burkholderia; Ceftolozane; Cystic fibrosis

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ANALOGS AND DERIVATIVES; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA GLADIOLI; BURKHOLDERIA INFECTION; CYSTIC FIBROSIS; DRUG COMBINATION; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA GLADIOLI; BURKHOLDERIA INFECTIONS; CEPHALOSPORINS; CYSTIC FIBROSIS; DRUG COMBINATIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID;

EID: 85028357426     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00766-17     Document Type: Article

References (11)

1. LiPuma JJ. 2010. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 23:299–323. https://doi.org/10.1128/CMR.00068-09.
2. Grohs P, Taieb G, Morand P, Kaibi I, Podglajen I, Lavollay M, Mainardi JL, Compain F. 17 January 2017. In vitro activity of ceftolozane-tazobactam against multidrug-resistant non-fermenting Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother https://doi.org/10.1128/AAC.02688-16.
3. Snydman DR, McDermott LA, Jacobus NV. 2014. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother 58:1218–1223. https://doi.org/10.1128/AAC.02253-13.
4. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 57:6305–6310. https://doi.org/10.1128/AAC.01802-13.
5. Craig WA, Andes DR. 2013. In vivo activities of ceftolozane, a new cephalo-sporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum -lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 57: 1577–1582. https://doi.org/10.1128/AAC.01590-12.
6. Kuti JL, Pettit RS, Neu N, Cies JJ, Lapin C, Muhlebach MS, Novak KJ, Nguyen KJ, Nguyen ST, Saiman L, Nicolau DP. 2015. Microbiologic activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagn Microbiol Infect Dis 83:53–55. https:// doi.org/10.1016/j.diagmicrobio.2015.04.012.
7. Payne GW, Vandamme P, Morgan SH, LiPuma JJ, Coenye T, Weightman AJ, Jones TH, Mahenthiralingam E. 2005. Development of a recA gene-based identification approach for the entire Burkholderia genus. Appl Environ Microbiol 71:3917–3927. https://doi.org/10.1128/AEM.71.7.3917-3927.2005.
8. Coenye T, Spilker T, Martin A, LiPuma JJ. 2002. Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III. J Clin Microbiol 40:3300 –3307. https://doi.org/10.1128/JCM.40.9.3300-3307.2002.
9. Clinical and Laboratories Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26th ed. CLSI Guideline M100. Clinical and Laboratories Standards Institute, Wayne, PA.
10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
11. Segonds C, Clavel-Batut P, Thouverez M, Grenet D, Le Coustumier A, Plésiat P, Chabanon G. 2009. Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli. J Clin Microbiol 47:1510–1516. https://doi.org/10.1128/JCM.02489-08.